PRV-3279-2a Trial in Systemic Lupus
Terminated · Phase 2 · NCT05087628
Conditions: Systemic Lupus Erythematosus
At a glance
- Research payments reported, 2025
- $147,026
- U.S. investigators named
- 18
- Sites paid
- 17
- Planned or actual enrollment
- 28
About the trial
- Sponsor
- Provention Bio, a Sanofi Company
- Tested
- PRV-3279 (biological), Placebo (other)
- Dates
- Started 2022-01-20; completion 2024-06-24
- Results posted
- Yes
The PREVAIL-2 study was designed to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) participants with active disease after amelioration induced by corticosteroid treatment.
From ClinicalTrials.gov, last updated 2026-04-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $147,026 in research payments for this study in 2025 (81 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Joann M. Ball, NP Nurse Practitioners · Palm Desert, CA
- Sue Y. Chung, MD. Rheumatology · Porter Ranch, CA
- Kenneth C. Kalunian, MD Rheumatology · San Diego, CA
- Maureen A. Mcmahon, MD Rheumatology · Los Angeles, CA
- Samy K. Metyas, MD Rheumatology · Covina, CA
- Tien I K. Su, M.D. Rheumatology · Whittier, CA
- Fotios Koumpouras, M. D. Rheumatology · North Haven, CT
- Ivette C. Espinosa-fernandez, DO General Practice · South Miami, FL
- Michael D. Kohen, M.D. Allergy & Immunology · Daytona Beach, FL
- Mazyar Rouhani, MD Emergency Medicine · Weaston, FL
- Alexander Torres, MD Rheumatology · Avon Park, FL
- Kimberly Trotter Rheumatology · Chicago, IL
- Chandana Keshavamurthy, M.D Rheumatology · New Orleans, LA
- Aleksander Feoktistov, MD Rheumatology · Brooklyn, NY
- Valerie R. Marrero Perea, MD Rheumatology · San Juan, PR
- Amarilis J. Perez Rheumatology · Caguas, PR
- Karina Vila-rivera, M.D. Rheumatology · San Juan, PR
- Philip A. Waller, M.D. Rheumatology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Biovin Enterprises Llc $16,738
- Harac Research Corp $15,980
- Facey Medical Group Northridge $15,468
- Amarilis J Perez De Jesus $13,151
- University of Chicago Medicine Psychiatry $12,267
- Gcm Medical Group Psc $11,750
- Ronald Reagan UCLA Medical Center, CA $11,566
- Yale University $10,817
- D and H Tamarac Research Center $7,560
- Metropolitan Hospital Center, NY $7,500
- University of California Davis Medical Center, CA $6,076
- Accurate Clinical Research Inc $5,598
- Brcr Medical Center Inc $2,950
- Desert Medical Advances $2,542
- Ochsner Medical Center Acute, LA $2,500
- Millennium Research LLC $2,150
- $1,643
- Revival Research Doral $770
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.